Ligand Reports Third Quarter 2026 Financial Results
Globe Newswire•29/10/2026•07:00 ET
0
Key Highlights
- ➤Royalty revenue $70.3 million, up 51% year-over-year
- ➤2026 adjusted diluted EPS guidance raised to $9.50-$9.75
- ➤2026 total revenue guidance reaffirmed at $270 million-$310 million
- ➤XOMA acquisition more than doubled portfolio to over 200 royalty assets
- ➤Qtorin rapamycin NDA receives FDA Priority Review; PDUFA date February 28, 2027
Expert Statements
Todd Davis, CEO of Ligand Pharmaceuticals
“Ligand delivered another strong quarter, with royalty revenue growing 51% year-over-year, driven by contribution from the XOMA portfolio and continued commercial momentum across our key royalty assets, including Filspari.”
Todd Davis, CEO of Ligand Pharmaceuticals
“We also continued to put capital to work in differentiated assets, acquiring a royalty interest in Santen’s Ryjunea and entering into a structured financing agreement with AvenCell Therapeutics to advance its next-generation CAR-T pipeline.”
Todd Davis, CEO of Ligand Pharmaceuticals
“With a strong balance sheet and a portfolio of over 200 assets, we are well positioned to continue executing our royalty aggregation strategy, and we look forward to sharing an updated five-year outlook at our investor day on December 8th.”
Third-quarter royalty revenue up 51% year-over-year to $70.3 million
Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.50(1); Reaffirms Revenue Guidance
Get started
Create a free account to read the full story.